þ hematopoietic progenitor and precursor cells (HPC) and their major B-cell and nonlymphoid compartments has been frequently reported in myelodysplastic syndromes (MDS). Here, we analyze for the first time the numerical and phenotypic abnormalities of different maturation-associated subsets of bone marrow (BM) CD34
Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders derived from the expansion of clonal hematopoietic cells with dysplastic features. 1 In MDS, expansion of clonal cells is frequently counterbalanced by massive intramedullary apoptosis leading to an ineffective bone marrow (BM) hematopoiesis and peripheral blood cytopenias. [2] [3] [4] Such alterations are associated with increased risk of transformation into acute leukemia due to acquisition of additional genetic and/or molecular abnormalities leading to inhibition of apoptosis 2, 3 and blockade of differentiation of early-frequently CD34
þ -myeloid progenitors. 5 
CD34
þ hematopoietic progenitor and precursor cells (HPC) are a heterogeneous cell population. Together with a small percentage of pluripotent stem cells, they include a major fraction of HPC already committed to different myeloid lineages (for example, erythroid, neutrophil, monocytic, dendritic cell (DC), basophil, mast cell (MC), eosinophil and megakaryocytic) together with CD34 þ B-cell precursors (BCP). 6 Previous studies have shown that quantification of BM CD34
þ HPC by flow cytometry is of great utility for the diagnosis and classification of MDS patients. [7] [8] [9] [10] [11] Apart from other aberrations, occurrence of phenotypic abnormalities on BM myeloblasts has also been reported in MDS. Among others, these include increased positivity for CD117, 4, 9, 12 CD15 and CD38, 9,11,13 aberrant CD4 dim9, 12 and CD11b expression 9 and decreased reactivity for CD38 and CD45, in a variable proportion of cases. 12, 14, 15 On top of this, Kussick et al. 4 also found abnormal expression of CD13, CD33 and HLA-DR on dysplastic CD34 þ myeloid precursors. In turn, some of these abnormalities have been associated with specific diagnostic and prognostic subtypes of MDS. Among other, altered expression of CD4 and CD45 has been associated with both refractory cytopenias with multilineage dysplasia (RCMD) and refractory anemia with excess of blasts (RAEB) as well as intermediate and high-grade MDS, but not RA with ringed sideroblasts (RARS), 12 while overexpression of CD34 on myeloblasts is more frequently observed in RAEB and RAEB in transformation, 16 and absence of BM CD34 þ / CD19 þ BCP in association with altered phenotypes of BM myeloblasts 8 is strongly associated with low-grade MDS; of note, the number and severity of the abnormalities detected on CD34 þ HPC from MDS patients appear to be directly related to disease category and prognosis. 12 Despite this, no study has been reported so far in which BM CD34 þ HPC showing phenotypic commitment to the different myeloid and Blymphoid compartments are specifically identified and characterized in MDS vs normal/reactive BM.
In the present study, we analyze the immunophenotypic characteristics of CD34 þ BM cells from MDS patients compared to normal/reactive BM. Our aim was to identify abnormalities in the distribution and phenotypic characteristics of the different compartments of immature and lineagecommitted CD34
þ HPC, that could contribute to distinguish between MDS and normal/reactive BM. Overall, our results show that most MDS patients display multiple phenotypic abnormalities and maturation-associated blockades in both myeloid-and lymphoid-committed CD34 þ precursors as well as in the more immature CD34 þ HPC. Interestingly, the number and degree of such alterations increased from low-to high-grade MDS patients.
Materials and methods

Patients, controls and samples
A total of 50 untreated patients (28 men and 22 women; mean age of 61 years, ranging from 31 to 85 years) with newly diagnosed MDS according to the WHO (World Health Organization) criteria 17, 18 were included in the present study. According to the WHO criteria patients were classified as follows: RA, 9 patients; RCMD, 11; RAEB-1, 7; RAEB-2, 16; myelodysplastic/myeloproliferative disorder (MD/MPD), 5 and unclassifiable MDS, 2 cases. According to the International Prognostic Scoring System (IPSS), 19 10 cases were classified as low-risk (LOW-R) MDS, 14 as intermediate-1 (INT-1-R), 9 as intermediate-2 (INT-2-R) and 4 cases as high-risk (HIGH-R) MDS; in the remaining 13 patients either metaphases could not be obtained from cultures or cytogenetic data was not available. For multiparameter flow cytometry immunophenotypic studies, EDTA-anticoagulated BM samples were obtained at diagnosis in all MDS cases.
In parallel, 29 freshly obtained EDTA-anticoagulated normal/ reactive BM samples from an identical number of individuals (median age 62 years; range 38-78 years) were collected at the University Hospital of Salamanca (Spain). Normal BM samples were obtained from healthy donors and individuals undergoing orthopedic surgery, while reactive BM samples corresponded to patients with carential and megaloblastic anemias, other toxic or reactive cytopenias (for example, idiopathic trombopenia purpura) and infection-associated leukocytosis/leucopenias. All BM samples were obtained after informed consent was given by each individual according to the recommendations of the local ethics committee.
Immunophenotypic studies and flow cytometry score
Whole BM samples (2 Â 10 6 cells in 100 ml per test) were stained for cell surface markers using a stain-lyse-and-then-wash, direct immunofluorescence technique, previously described in detail. 20, 21 In addition, intracellular nuclear (n) and cytoplasmic (Cy) stainings were performed after cell fixation and permeabilization, using the Fix and Perm reagent kit (Invitrogen, Carlsbad, CA, USA). The following combinations of monoclonal antibodies (MAb) in four color stainingsFfluorescein isothiocyanate/phycoerythrin/peridinin chlorophyll protein/allophycocyaninFwere systematically used: HLA-DR/CD117/CD45/CD34; HLA-DR/CD123/CD45/CD34; CD11b/CD13/CD45/CD34; CD61/ CD33/CD45/CD34; nTdT/CyMPO/CD45/CD34; CD15/CD16/ CD45/CD34; CD19/CyCD79a/CD45/CD34; CD65/7.1/CD45/CD34; CD36/CD64/CD45/CD34-CD14 and CyCD3/CD7/CD45/CD34. The specificity and source of each reagent used are listed in Table 1 .
Data acquisition was performed in two consecutive steps immediately after sample preparation was completed, using a FACSCalibur flow cytometerFBecton Dickinson Biosciences (BDB), San Jose, CA, USAFand the CellQUEST software program (BDB). In the first step, information about a total of 30 000 events per tube corresponding to the whole BM cellularity was acquired; in the second step, information on a minimum of 3 Â 10 3 CD34 þ cells was specifically acquired through an electronic gate. For data analysis, both the PAINT-A-GATE PRO (BDB) and INFINICYT (Cytognos SL, Salamanca, Spain) software programs were used. As illustrated in Figure 1 , three major subsets of BM CD34 þ HPC were identified in normal/reactive BM samples on the basis of their different forward (FSC) and sideward (SSC) light scatter characteristics and their reactivity for the CD45 and CD34 antigens. These subsets were mainly composed of (1) (Figure 1h ) and (5) CD34 þ -nucleated erythroid precursors were identified as being CD36 þ /CD64 À / CD45 lo ( Figure 1f ). Gating of CD34 þ HPC was performed based on the patterns of light scatter and CD45 expression of CD34 þ cells, following the ISHAGE guidelines 25 and using the residual mature lymphocytes and neutrophils as a reference. Briefly, CD34
þ HPC were identified as those events showing reactivity for CD34 over autofluorescence levels and dim CD45 þ HPC based on numerical and phenotypic deviations from the normal/reactive BM profiles, which were greater than the mean ± two standard deviations (s.d.). Of note, as illustrated in Figure 1b vs Figure 1d , scatter gating was adapted to those stainings containing intracellular markers where cells were submitted to fixation and permeabilization procedures as described above. Instrument setup, calibration and quality control was checked during the study using commercial standard reagents (Spherocaliflow QC kit; Spherotec, Lybertyville, IL, USA) and should follow rules, previously described in detail. 26 For the individual abnormalities detected for each of the 27 immunophenotypic variables analyzed, (Table 2) a score was defined. Accordingly, a score of 0.5, 1 or 2 was given when the value obtained for each of these parameters was between the mean ± 2 s.d. and the mean ± 3 s.d., between the mean ± 3 s.d. and the mean ± 4 s.d. and, over the mean ± 4 s.d. of the values found for that parameter among the normal/reactive BM samples analyzed, respectively.
Conventional karyotyping and fluorescence in situ hybridization studies
Cytogenetic analysis of BM samples was performed according to standard procedures 27 and interpreted using the International System for Cytogenetic Nomenclature criteria. 28 In addition, interphase fluorescence in situ hybridization (iFISH) studies were systematically performed on 40 MDS BM samples according to previously reported techniques. 29 In these cases, the following chromosome probes purchased from Vysis Inc (Downers Grove, IL, USA) were used in double stainings, for the detection of the most frequent recurrent abnormalities: (1) þ hematopoietic progenitor and precursor cells (HPC) were differentially identified in a normal BM sample. In (a-d), the gating strategy for the major subsets of immature (red events), B-lymphoid (green dots) and neutrophil (blue dots) CD34 þ precursors is shown both for cell surface-only stainings (d) and for both cell surface and intracellular markers (b); gray events in (a) correspond to CD34 À BM cells. In (e-h), identification of minor subsets of CD34 þ HPC is illustrated; accordingly, identification of plasmacytoid dendritic cells (pDC) and basophil precursors is illustrated in (e) (red and blue dots, respectively), while (f and g) illustrate how CD34 þ monocytic (pink dots) and erythroid (cyan dots) were identified; (h) early maturation of CD34 þ HPC into the mast cell (MC) lineage (red dots). 
Statistical methods
For all variables under study, their mean values and s.d., median and range were calculated using the SPSS software (SPSS 10.0, Chicago, IL, USA). Comparisons between two or more groups were made using the Student's t-test (for parametric data) and either the Mann-Whitney U or the Kruskal-Wallis tests (for nonparametric data). P-values o0.05 were considered to be associated with statistical significance.
Hierarchical clustering analysis was performed with a total of 65 samples, which had complete data, corresponding to both normal/reactive (n ¼ 29) and MDS (n ¼
In order to explore the predictive value of the distribution and patterns of expression of the different markers analyzed in the distinct subsets of CD34 þ HPC, for the classification of cases as normal/reactive BM vs LOW-R and HIGH-R MDS, a class predictor was built using a weighted voting algorithm, evaluated with a leave-one-out cross validation procedure. For this purpose, a training set with half of the normal/reactive (n ¼ 14) and MDS BM samples (n ¼ 19) included in the hierarchical clustering analysis was used; in this part of the study, patients were grouped according to the WHO and IPSS classifications. The accuracy of the predictor was then tested in the remaining individuals, using the nearest shrunken centroids method (PAM software; http://www-stat.stanford.edu/~tibs/PAM). 30 
Results
Distribution of total BM CD34
þ HPC and their subsets in MDS As expected, the overall percentage of BM CD34 þ HPC was significantly increased in a major proportion (40%) of all MDS cases (Table 2) , mainly corresponding to the RAEB-2 (Po0.001) and MD/MPD (P ¼ 0.02) WHO subgroups and the INT-1-R (P ¼ 0.03), INT-2-R (P ¼ 0.001) and HIGH-R MDS cases (Po0.001) (Supplementary Table 1) . A more detailed analysis of the distribution of the major subsets of BM CD34 þ HPC showed that while the more immature CD34 þ precursors were abnormally increased in 16% of the cases (Table 2) F particularly in the advanced stages of the disease: RAEB-1 (P ¼ 0.003), RAEB-2 (P ¼ 0.005), INT-1-R (P ¼ 0.01), INT-2-R (P ¼ 0.002) and HIGH-R MDS patients (P ¼ 0.02) (Supplementary Table 1)FCD34 þ BCP tended to disappear in the same subgroups of MDSF65% of all MDS patientsF(Po0.001 vs normal/reactive BM) ( Table 2; Supplementary Table 1) . Because of these changes, the ratio between the percentage of CD34 þ BCP and that of CD34 þ immature precursors tended to zero in a high proportion (60%) of MDS patients. Overall, BCP could only be identified in 7% of cases in advanced stages of the disease, while they were decreased below normal values among the other groups of MDS patients in between 50% (RA cases) and 100% (RAEB-2, INT-2-R and HIGH-R patients) of the cases (Supplementary Table 1 ). In turn, neutrophil precursors were altered in 45% of all MDS patients (P ¼ 0.001) ( Table 2) , around one-half of the cases showing increased (24%) and the other half, decreased (21%) values. Of note, increased values of CD34 þ neutrophil precursors were mainly found among RA and LOW-R MDS cases, while abnormally low percentages of these cells were detected in RAEB-1 and HIGH-R cases (Supplementary Table 1) .
Upon considering those subsets of CD34 þ HPC represented at low frequencies in normal/reactive BM (Table 2) significant changes were detected in the distribution of plasmacytoid DC precursors, which were decreased in 60% of all MDS cases (Po0.001). Additionally, altered numbers of CD34 þ erythroid HPC (Po0.001), basophil (P ¼ 0.03) and monocytic precursors (P ¼ 0.006) were also found in 54, 46 and 32% of all MDS patients, respectively (Table 2 ). In contrast, no statistically significant differences were found in the distribution of CD34 þ MC precursors in MDS, as compared to normal/reactive BM ( Table 2 ).
Immunophenotypic characteristics of the major subpopulations of immature, neutrophil and B cell-committed BM CD34 þ precursors in MDS All three major subsets of BM CD34 þ HPC from MDS patients showed multiple phenotypic differences in their patterns of antigen expression with respect to normal/reactive BM. Detailed information about the frequency of cases showing altered phenotypes on immature, neutrophil and BCP is provided in Table 2 . As displayed in it, immature precursors showed increased expression of the CD13, CD33 and/or CD117 myeloid-associated markers in 40, 20 and 46% of MDS cases, respectively, such abnormalities being more frequently observed among high-vs low-grade MDS patients (Supplementary Table 1 ). In turn, CD7 expression was also altered on immature precursorsFmostly decreasedFin almost half (41%) of the patients (Table 2) ; interestingly, no significant differences were observed between the different subgroups of MDS patients, except for HIGH-R cases that more frequently showed increased percentages of CD7 þ cells (Supplementary Table 1 ). In contrast, expression of CD45 and HLA-DR on immature precursors was found to be altered in only a relatively small percentage of cases (14 and 8%, respectively).
Similarly, increased patterns of expression of CD13 (20%) and CD117 (30%) were found among neutrophil precursors within the different subtypes of MDS, while CD33 was more frequently decreased (11% cases showed increased and 23% decreased expression of this marker), independently of the diagnostic subgroup (Table 2; Supplementary Table 1 ). This was associated with an abnormally decreased reactivity for other neutrophil lineage-associated markers such as CyMPO (13%), CD64 (30%) and CD65 (15%), and both a decreased (30%) and increased (11%) percentage of CD15 þ cells on neutrophil precursors. A significant proportion of MDS cases in which CD34 þ BCP were found, showed abnormally decreased expression of CyCD79a (75% of the cases) and nTdT (25%), associated with variable patterns of expression of HLA-DR.
No abnormalities were detected for the other phenotypic markers analyzed, including 7.1 ( Table 2) .
Classification of MDS patients according to the patterns of expression of multiple phenotypic markers on specific subsets of CD34 þ HPC Hierarchical clustering analysis of flow cytometry immunophenotypic data about different subsets of CD34 þ HPC (Figure 2) showed that most normal BM samples (83%) clustered together and were clearly separated from both the MDS cases and reactive BM samples. Among these latter cases, two A detailed analysis of the patterns of antigen expression in BM CD34
þ HPC from the different groups of samples analyzed ( Figure 2) shows marked alterations in the CD34 þ compartment of B-cell and plasmacytoid DC precursors, which mainly affect high-grade MDS cases; together with increased expression of CD13 in both immature and neutrophil precursors, these were the most discriminative parameters. Of note, MDS and normal/ reactive BM cases, which apparently overlap in the clusters, could be further discriminated by the existence of decreased expression of granulomonocytic-associated markers (for example, CD65, CD64, CD15 and CyMPO), as illustrated for individual cases in Figure 2 . In fact, once a class predictor was applied to explore the value of the different markers analyzed in classifying cases as normal/reactive BM vs LOW-R and HIGH-R MDS, the most relevant markers in the predictive model were the percentage of total BM CD34 þ cells as well as that of B-cell and plasmacytoid DC precursors, together with the expression of CD13 on both immature and neutrophil CD34 þ precursors and of CyCD79a on CD34 þ BCP (Figure 3 ). Other markers in the predictive model were the expression of CD33 and CD117 on both immature and neutrophil precursors, in addition to that of CD45, HLA-DR and CD65 on the latter CD34 þ cell subset. Due to the high variability observed in individual MDS cases, an immunophenotypic score was then built (see 'Materials and methods') based on the degree of deviation from the normal phenotypic patterns and the number of abnormalities detected for the 27 phenotypic variables listed in Table 2 . According to this score, a clear discrimination between normal/reactive (scorep0.5) and MDS patients (scoreX1) was obtained (Table 3) . Interestingly, the mean score of MDS cases increased from low-to high-grade cases both when the different subgroups of MDS patients were defined by the IPSS and the WHO classifications (Table 3 ). þ myeloid progenitors, together with decreased CD34 þ / CD10 þ BCP. Other frequently reported abnormalities consist of (1) altered expression of CD11b and CD15, (2) negativity for CD13, CD33 and/or HLA-DR, (3) cross-lineage expression of CD5, CD7, CD19 and /or CD56, (4) overexpression of CD34 and, (5) abnormally low amounts of CD45, CD38 and CD34. 33 However, in these studies, phenotypic data is referred to the overall population of BM CD34 þ HPC or their major B-cell and nonlymphoid compartments, without exploring the biological basis for such alterations, and/or identifying criteria for a 100% efficient discrimination between MDS and normal/reactive BM.
In this study, for the first time we analyze the numerical and immunophenotypic abnormalities present in different maturation-associated subsets of immature and myeloid-committed CD34
þ HPC in addition to CD34 þ BCP from MDS vs normal/ reactive BM. In addition, we propose a scoring system, which might be used in the future to predict outcome in MDS. Accordingly, all MDS cases analyzed revealed the existence of highly variable maturation-associated abnormalities among the different subsets of CD34
þ HPC, such alterations consisting of an abnormal distribution of the different CD34 þ HPC compartments and/or abnormal expression of specific cell surface and/or intracellular antigens. As expected, such heterogeneous abnormalities varied from the early low-grade to the more advanced high-grade MDS cases. In line with previous reports, 11, 34 detailed analysis of the distribution of BM CD34 þ HPC and their subsets showed a parallel increase in the overall percentage of CD34 þ cells and disease risk. Such increased number of CD34 þ cells was mainly due to a progressive expansion of immature precursors found to be abnormally increased in most high-grade MDS cases. In line with previous observations from our 35 and other groups, 36 the increase of immature precursors was associated with decreased numbers of BCP and, to a lower extent, also of neutrophil, plasmacytoid DC, basophil and erythroid-committed CD34 þ HPC, except among low-grade MDS cases, where a shift toward the production of neutrophil and erythroid lineage cells, at the expense of B-cell and plasmacytoid DC precursors, was observed in a significant proportion of cases.
Altogether, these findings point out the existence of a variable degree of impairment of BM hematopoiesis among different subtypes of MDS, the ability of HPC for multilineage differentiation progressively decreasing in the more advanced, poor prognosis disease categories in line with the occurrence of progressive, marked, multiple cytopenias among high-grade MDS cases. In line with these findings, previous reports have shown the existence of different gene expression profiles among CD34 þ cells from LOW-and HIGH-R MDS associated with disease progression (for example, downregulation of several so-called defensive proteins such as RAI2 and IEX1), suggesting that MDS CD34 þ cells may accumulate genetic defects that progressively prevent hematopoietic differentiation. 37 In addition, the occurrence of functional and structural abnormalities in the hematopoietic microenvironment during disease progression have also been reported, which might translate into a selective defect in the ability of BM stroma of high-grade MDS patients to support maturation of uncommitted HPC, as found for acute myeloid leukemia (AML). 38, 39 In line with this hypothesis, a progressive shift toward an immature and very early neutrophil-lineage precursor phenotype was also observed among both CD34 þ immature and neutrophil precursors from low-to high-grade MDS, with a progressively higher expression of both CD117 and CD13 together with a lower reactivity for more specific neutrophil markers (for example, MPO, CD64 and CD65). Of note, CD13 expression was found to be decreased in the very early phases of the disease (RA) in parallel to the slightly higher frequency of CD34 þ erythroid-committed HPC observed in these patients, in association with decreased numbers of CD34 þ /CD15 þ cells. Although these results require confirmation in larger studies, they would support the hypothesis that a shift toward erythroid differentiation could occur in this subgroup of low-grade MDS patients. In line with this, we also found altered levels of CD33 among CD34 þ NP, consisting of an abnormally low expression in low-grade MDS (RA, RCMD, INT-1 and LOW-R cases) and significantly increased amounts in RAEB-2 cases.
In a previous report, Jilani et al. 40 described low expression of CD33 on MDS CD34 þ cells. However, in this study the intensity of CD33 expression was measured in the whole CD34 þ HPC population from a mixed group of MDS patients with different FAB subtypes. In turn, Ogata et al. 8 found CD13, 
CD34
þ cells phenotype in myelodysplastic syndromes S Matarraz et al CD33 and CD117 overexpressed on CD34 þ myeloblasts from a group of 12 patients with low-grade MDS and determined that the most frequent alterations in such patients were the decrease in the percentage of BCP (67% or patients), followed by increased CD15 (50%) and CD117 (33%) expression. In our series, low-grade MDS cases also showed decreased numbers of BCP as the most common alteration (50% of cases), while increased CD15 expression was found in only 1/20 cases. In addition, CD117 was abnormally increased in around onefourth of all low-grade MDS cases, while CD13 and CD33 overexpression was restricted to patients with advanced disease. Of note, the observation of CD13 overexpression in high-grade MDS patients suggests that CD13 may play a key role in the development of different rates of apoptosis between distinct MDS-risk groups, because deregulated expression of this cell surface N-peptidase has been associated with an increased resistance to undergo interleukin-8-mediated apoptosis, which is reversed by specific CD13 protease inhibitors (for example, bestatin). 41 Although our results require further confirmation in larger studies, abnormally increased expression of CD7, CD11b and CD56 was rarely detected in CD34 þ HPC from our MDS patients, in contrast to what is known about 'de novo' AML blast cells.
In line with previous observations, 35 BCP were not only progressively decreased in number from low-to high-grade MDS, but they also showed a pronounced aberrant phenotype characterized by abnormally decreased expression of CD79a, associated with decreased TdT and HLA-DR expression among INT-1 and LOW-R MDS cases, respectively. Altogether, these results indicate that a progressively decreased and abnormal production of B-lymphocytes might occur in MDS from low-to high-grade cases, as also suggested by others. 35, 36, 42 Whether B cells in MDS are also derived from the neoplastic clone or these abnormalities just reflect a shift toward the production of myeloid cells essential to patient survival remains a matter of debate and requires further investigations.
On the basis of the observations of such marked differences in the distribution and phenotypic characteristics of different subsets of CD34 þ HPC in MDS vs normal/reactive BM, a multivariate hierarchical cluster analysis was performed. Overall, this analysis showed that while CD34 þ HPC are clearly different from normal precursors in high-grade MDS, there appears to be a significant degree of overlap between reactive BM and low-grade MDS cases. In line with this, the predictive value of the most informative independent phenotypic parameters analyzedFoverall number of CD34 þ cells, CD34 þ BCP and CD34 þ plasmacytoid DC precursors, together with the expression of CD13, CD117 and CyCD79aFreached an efficiency of close to 80 and 100% on identifying normal/ reactive vs LOW-R and HIGH-R MDS patients, respectively. However, once a phenotypic scoring system similar to that reported by Ogata et al. 8 in which the number of phenotypic abnormalities and their degree of deviation from normal values were considered, a 100% efficient discrimination was obtained between normal/reactive BM and MDS cases, the mean score increasing from low-to high-grade MDS patients. 0.08 ± 0.1 3.5 ± 2 5 ± 3 9 ± 4 14 ± 3 7 ± 5 6 ± 6.5 2.4 ± 1.5 6.5 ± 1.6 10.5 ± 4.5 9 ± 3 7 ± 5
Abbreviations: BM, bone marrow; HIGH-R, high-risk MDS; INT-2-R, intermediate-2 MDS; IPSS, International Prognostic Scoring System; LOW-R, low-risk MDS; MD/MPD, myelodysplastic/myeloproliferative disorder; MDS, myelodysplastic syndromes; RA, refractory anemia; RAEB, refractory anemia with excess of blasts; RCMD, refractory cytopenias with multilineage dysplasia.
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